Agree Ram,
The report did show yesterday what everyone already knew about revenue the last year and it seems quiet a few more are expecting this to change in the near term and have backed it heavier over the past year.
2021 report had total holders breakdown as follows
10,000 up to 100,000 shares 3665 shareholders
over 100,000 shares 1664 shareholders
This years report had total holders breakdown as follows-
10,000 up to 100,000 shares 4216 shareholders a gain of 551 new comers
over 100,000 shares 1832 shareholders a gain of 168 new comers
The smaller holdings under 10,000 are probably still very relevant for volume of churn and day to day SP as they look to make a few extra bucks lunch money here and there, like you do Ram as they still account for around 20M shares and good luck to them.... but it seems there are now 719 more people/entities in the larger amounts side of the register.
Larger holdings over 100,000 shares are still over 90% of those on issue 1.8B odd, takeout the top 20 holding of 555,000,000 there are 1.25B left held by 1782 different entities for an average of 700,000 shares each.
The top 20 shareholders and option holders also remains pretty solid relatively unchanged with a few slightly up and a few slightly down.
Seems like a pretty solid core base of holders/believers in where this could head next, of those I know personally in the over 100,000 holding category they didn't sell any at 40c and quiet a few have increased the size of their holding recently while it is below 10c.
As you say revenue is needed to grow this beast but market caps tend to increase before the $$$ actually hit the balance sheet, one sniff of a regulatory approval for Covid test by WHO, TGA or EU commons (we have now been given some realistic timelines and given Alfred trial went so well no reason to think this one wont and have stated manufacturing issues are resolved and several other distributors awaiting EU listing) or interest from a battery collaborator (they have a pretty interesting Energy advisory board in place along with validation underway with 26 companies looking into uses for the tech, so anything could happen here) or diagnostic test manufacturer (have had mention of various other manufacturers looking to incorporate Anteobind into their test range and Ellume are about to get automation underway in US) and things will get interesting very quickly again.
Looking forward to catching up with a few at the AGM and hearing the strategy from the new look board in person.
GLTA
Expand
